Novo’s US head is ready for turnaround
The head of Novo Nordisk’s North American business, Jakob Riis, has made the necessary changes to facilitate a turnaround in his first five months in the job. He now has the freedom and room to maneuver that should lead to twice as big a share of the market for the group's major insulin hope.
BY STEFAN SINGH KAILAY
“I have been given a mandate to find out how we ensure a very strong performance in the US and I have a very strong mandate from both Larses (Rebien Sørensen and Fruergaard Jørgensen, ed.). In that sense I feel in many ways that I have been given responsibility and freedom to operate in the US with the support of both the management and Board. There’s a strong CEO element in the position I have been given here.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s US boss wants to kick Tresiba sales into gear
For abonnenter
Open letter from Novo VP: We will limit price hikes
For abonnenter
